Delving into the Latest Updates on Cilostazol/Decanol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

西洛他唑/冰片

+ [1]

Target

PDE3

Action

inhibitors

Mechanism

PDE3 inhibitors(Phosphodiesterase 3 inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases

Active Indication

occlusionsAcute Ischemic StrokeCognition Disorders

Inactive Indication-

Originator Organization

Neurodawn Pharmaceutical Co., Ltd.

Active Organization

Neurodawn Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H22O

InChIKeyMWKFXSUHUHTGQN-UHFFFAOYSA-N

CAS Registry112-30-1

View All Structures (2)

This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.

Start Date01 Nov 2023

Sponsor / Collaborator

Beijing Tiantan Hospital

[+1]

ChiCTR2400081678

/ RecruitingPhase 2IIT

Phase clinical trial of Y-6 sublingual tablets for acute ischemic stroke —— multicenter, randomized, double-masked, placebo parallel controlled trial - FUTURE trial

Start Date13 Oct 2023

Sponsor / Collaborator-

100 Clinical Results associated with Cilostazol/Decanol

Login to view more data

100 Translational Medicine associated with Cilostazol/Decanol

Login to view more data

100 Patents (Medical) associated with Cilostazol/Decanol

Login to view more data

15

Literatures (Medical) associated with Cilostazol/Decanol

01 Feb 2022·Advanced ScienceQ1 · MATERIALS SCIENCE

High‐Efficiency Non‐Fullerene Acceptors Developed by Machine Learning and Quantum Chemistry

Q1 · MATERIALS SCIENCE

ArticleOA

Author: Odunmbaku, Omololu ; Ou, Zeping ; Li, Jing ; Sun, Kuan ; Sun, Wenbo ; Zheng, Yu Jie ; Li, Meng ; Qin, Bo ; Zhou, Yongli ; Zhang, Qi ; Chen, Shanshan

AbstractY6 and its derivatives have greatly improved the power conversion efficiency (PCE) of organic photovoltaics (OPVs). Further developing high‐performance Y6 derivative acceptor materials through the relationship between the chemical structures and properties of these materials will help accelerate the development of OPV. Here, machine learning and quantum chemistry are used to understand the structure–property relationships and develop new OPV acceptor materials. By encoding the molecules with an improved one‐hot code, the trained machine learning model shows good predictive performance, and 22 new acceptors with predicted PCE values greater than 17% within the virtual chemical space are screened out. Trends associated with the discovered high‐performing molecules suggest that Y6 derivatives with medium‐length side chains have higher performance. Further quantum chemistry calculations reveal that the end acceptor units mainly affect the frontier molecular orbital energy levels and the electrostatic potential on molecular surface, which in turn influence the performance of OPV devices. A series of promising Y6 derivative candidates is screened out and a rational design guide for developing high‐performance OPV acceptors is provided. The approach in this work can be extended to other material systems for rapid materials discovery and can provide a framework for designing novel and promising OPV materials.

01 Jan 2021·Food ChemistryQ1 · AGRICULTURAL & FORESTRY SCIENCE

Path analysis of non-enzymatic browning in Dongbei Suancai during storage caused by different fermentation conditions

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Wu, Xingzhuang ; Han, Yanqiu ; Zhang, Xiaoli ; Gao, Ya ; Wang, Chen

A non-enzymatic browning reaction occurs easily in Dongbei Suancai (DS) during storage. Using the method of path analysis, the changes in contents of VC (ascorbic acid), polyphenol, reducing sugar, amino nitrogen, and 5-HMF (5-hydroxymethyl furfural) were investigated to analyze the direct pathways and determinants of browning caused by pre-production blanching at 100 °C (R-100), salt-addition increased from 2% to 6% (Y-6) and fermentation time extended from 30 d to 40 d (T-40), respectively. The results showed that R-100 could delay the browning by inhibiting two direct pathways of oxidative decomposition of VC and oxidation-polymerization of polyphenols, but T-40 could lead to an increase in degree of browning for which primary determinant was the interaction between polyphenol and reducing sugar, while Y-6 had no obvious effect on browning pathway and determinants. R-100 was thus deemed to be a good measure with inhibiting non-enzymatic browning in DS during storage.

09 Sep 2020·Journal of the American Chemical SocietyQ1 · CHEMISTRY

A Non-fullerene Acceptor with Enhanced Intermolecular π-Core Interaction for High-Performance Organic Solar Cells

Q1 · CHEMISTRY

Article

Author: Kaminsky, Werner ; Jen, Alex K.-Y. ; Zhu, Zonglong ; Jiang, Kui ; Lin, Francis

Understanding the molecular structure and self-assembly of thiadiazole-derived non-fullerene acceptors (NFAs) is very critical for elucidating the origin of their extraordinary charge generation and transport properties that enable high power conversion efficiencies to be achieved in these systems. A comprehensive crystallographic study on a state-of-the-art NFA, Y6, and its selenium analog, CH1007, has been conducted which revealed that the face-to-face π-core interaction induced by benzo[2,1,3]thiadiazole S-N-containing moieties plays a significant role in governing the molecular geometries and unique packing of Y6 and CH1007 to ensure their superior charge-transport properties. Moreover, benefitting from the red-shifted optical absorption via selenium substitution, photovoltaic devices based on a PM6:CH1007:PC₇₁BM ternary blend delivered an exceptionally high short-circuit current of 27.48 mA/cm² and a power conversion efficiency of 17.08%.

100 Deals associated with Cilostazol/Decanol

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
occlusions	Phase 2	-	Neurodawn Pharmaceutical Co., Ltd.	01 Nov 2023
Acute Ischemic Stroke	Phase 2	China	Neurodawn Pharmaceutical Co., Ltd.	05 Jun 2023
Cognition Disorders	Preclinical	China	Neurodawn Pharmaceutical Co., Ltd.	01 Dec 2024